Newsletter

069620 - Daewoong Pharma

069620 Summary

Biopharma

Stock Price & Overview

₩114,400 -1,200 (-1.04%) Close · Sep 9, 2026 KST

KOSPI | ₩KRW | Close: ₩114,400 ≈ US$82 · Market cap ₩1.3tn (≈ $947m)

Home › 069620 › Filings

Results of an extraordinary general meeting

DART

Daewoong Pharma

Filed Sep 9, 2026 KST · Filing · receipt 20260909800396

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.

Korean form name: 임시주주총회결과

069620

Price: ₩114,400
Change: -1.04%
Market cap: ₩1.3tn
Prev. close: ₩115,600

069620 Summary Compare to Peers

069620 data on kstock

Financials: 11 fiscal years
Valuation: Daily P/E, P/S, P/B, P/CF
Earnings: Eight quarters
Dividends: Per-share history

Every figure is taken from Daewoong Pharma's own DART filings and matched on IFRS account codes, so a line holds across years where the Korean wording changed.

More 069620 filings

069620 - Daewoong Pharma

Results of an extraordinary general meeting

069620

069620 data on kstock

More 069620 filings

Appointment, dismissal or early departure of an independent director

Debt guarantee for a third party

Litigation Filed

Proxy solicitation reference document

Notice of general meeting of shareholders

Insider / Major Shareholder Holdings Report